Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- LifeBridge Health
- Target Recruit Count
- 400
- Registration Number
- NCT01869309
- Locations
- 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
- Conditions
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT01864005
- Locations
- 🇨🇳
Research Site, Tianjin, China
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 110
- Registration Number
- NCT01852175
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 50
- Registration Number
- NCT01852214
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
The Antiplatelet and Immune Response Trial
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2021-09-27
- Target Recruit Count
- 30
- Registration Number
- NCT01846559
- Locations
- 🇬🇧
Sheffield Clinical Research Facility, Sheffield, South Yorkshire, United Kingdom
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 2124
- Registration Number
- NCT01830543
The ACS Ethnicity Platelet Function Study
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 4
- Registration Number
- NCT01829659
- Locations
- 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study
- Conditions
- Interventions
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01826175
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- ECRI bv
- Target Recruit Count
- 15991
- Registration Number
- NCT01813435
- Locations
- 🇧🇪
Research centre Aalst, 3201, Aalst, Belgium
🇧🇪Research centre Genk, 3205, Genk, Belgium
🇦🇹Research centre Graz, 4305, Graz, Austria
Efficacy and Safety Study of Ticagrelor
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- General Hospital of Chinese Armed Police Forces
- Target Recruit Count
- 180
- Registration Number
- NCT01812330
- Locations
- 🇨🇳
General Hospital of Chinese People's Armed Police Forces, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.